Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $631K rose 28.5% year over year, behind the +35.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 12.1% from the prior quarter. Over 3 fiscal years it compounded at -25.1% a year.
Context
- Depreciation & amortization amounted to 54.2% of revenue in FY2025, down 29.0 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +28.5% toward the trailing-twelve-month pace of +35.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.2M USD
- Year-over-year change
- +40.5%
- 4-year CAGR
- -15.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.2M | +40.5% |
| FY2024 | 2024-12-31 | 1.56M | -6.9% |
| FY2023 | 2023-12-31 | 1.68M | -67.8% |
| FY2022 | 2022-12-31 | 5.22M | +24.1% |
| FY2021 | 2021-12-31 | 4.21M | — |
Depreciation & Amortization vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 depreciation & amortization of $2.34M is the 6th largest of the 10 companies compared; the peer median is $3.2M.
- Its year-over-year change of +35.9% is the 5th highest of 10, against a peer median of +16.3%.
- Depreciation & amortization amounts to 119.9% of revenue for IMDX, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.65M | +1.1% | +6.0% | 81.8% | |
| LTM Mar 2026 | $6.75M | +171.1% | -20.0% | 8.6% | |
| LTM Mar 2026 | $6.56M | -25.2% | -28.2% | 19.0% | |
| LTM Mar 2026 | $3.38M | +84.9% | +5.3% | 9.7% | |
| LTM Mar 2026 | $3.2M | -5.6% | +118.5% | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| LTM Mar 2026 | $1.88M | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.61M | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $1.53M | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $143K | +37.5% | +8.6% | 8.0% | |
| Peer median (excluding IMDX) | $3.2M | +16.3% | +6.0% | 9.4% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Deferred Income Tax | (9.26M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.84M | 10.04M | 6.57M | 1.91M | 2.22M |
| Change in Working Capital | 149K | (1.94M) | (3.97M) | (1.32M) | 2.73M |
| Accounts Receivables | (1.23M) | (575K) | 109K | (1.13M) | 485K |
| Inventory | 0 | 0 | 0 | (410K) | (36K) |
| Accounts Payables | (1.35M) | 297K | (4.76M) | 967K | 2.65M |
| Other Working Capital | 2.73M | (1.66M) | 677K | (749K) | (368K) |
| Other Non-Cash Items | 26.22M | 14.01M | 174K | 37.79M | 20.9M |
| Operating Cash Flow | (35.94M) | (45.57M) | (23.33M) | (20.71M) | (22.18M) |
| Capital Expenditures | (2.25M) | (4.34M) | (281K) | (516K) | (3.19M) |
| Acquisitions (Net) | (11.71M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 367K | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1.02M) | 4K | 0 |
| Investing Cash Flow | (13.96M) | (4.34M) | (932K) | (512K) | (3.19M) |
| Debt Repayment | (1.53M) | (1.43M) | (117K) | (201K) | (510K) |
| Common Stock Issued | 77.99M | 32.84M | 13.85M | 27.81M | 28.66M |
| Common Stock Repurchased | (239K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.15M | (483K) | (427K) | (1.8M) | (74K) |
| Financing Cash Flow | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 973K |
| Net Change in Cash | 28.46M | (14.1M) | (12.07M) | (796K) | 3.68M |
| Free Cash Flow | (38.19M) | (49.91M) | (23.61M) | (21.23M) | (25.37M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.